This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Articles

Risperidone for the Treatment of Behavioral and Psychological Symptoms of Dementia

Larry E. Tune, MD

Published: January 7, 2001

Article Abstract

Risperidone offers physicians the unique combination of extensive, published clinical experienceand a good safety profile for treating patients with dementia who have symptoms of aggression, agitation,and psychosis. Numerous open-label and, more recently, placebo-controlled trials have documentedthe efficacy of risperidone in the management of behavioral and psychological symptoms ofdementia. These trials also show that risperidone is better tolerated than conventional neurolepticagents. Comparatively, patients treated with risperidone experience substantially fewer side effects,including extrapyramidal symptoms, cognitive toxicity, and tardive dyskinesia.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 62

Quick Links: Dementia , Neurologic and Neurocognitive

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...